LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 33

Search options

  1. Conference proceedings: Wenn zu viel Medizin krank macht – Gemeinsam gut entscheiden gegen Überversorgung

    Meixner, Jana / Glechner, Anna

    2020  , Page(s) 20ebmPP6–01

    Event/congress 21. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin; Nützliche patientenrelevante Forschung; Basel, Schweiz; Deutsches Netzwerk Evidenzbasierte Medizin e.V.; 2020
    Keywords Medizin, Gesundheit
    Publishing date 2020-02-12
    Publisher German Medical Science GMS Publishing House; Düsseldorf
    Document type Conference proceedings
    DOI 10.3205/20ebm089
    Database German Medical Science

    More links

    Kategorien

  2. Article: Risk of Contrast-Associated Acute Kidney Injury in Patients Undergoing Peripheral Angiography with Carbon Dioxide Compared to Iodine-Containing Contrast Agents: A Systematic Review and Meta-Analysis.

    Wagner, Gernot / Glechner, Anna / Persad, Emma / Klerings, Irma / Gartlehner, Gerald / Moertl, Deddo / Steiner, Sabine

    Journal of clinical medicine

    2022  Volume 11, Issue 23

    Abstract: The aim of this systematic review was to summarise the comparative evidence on the risk of contrast-associated acute kidney injury (CA-AKI) with ... ...

    Abstract The aim of this systematic review was to summarise the comparative evidence on the risk of contrast-associated acute kidney injury (CA-AKI) with CO
    Language English
    Publishing date 2022-12-04
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm11237203
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Conference proceedings: Visuelle Abstracts für Rapid Reviews

    Fangmeyer, Martin / Toromanova, Ana / Glechner, Anna

    2021  , Page(s) 21ebmPS–5–01

    Event/congress 22. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin; Who cares? – EbM und Transformation im Gesundheitswesen; sine loco [digital]; Deutsches Netzwerk Evidenzbasierte Medizin e.V.; 2021
    Keywords Medizin, Gesundheit
    Publishing date 2021-02-23
    Publisher German Medical Science GMS Publishing House; Düsseldorf
    Document type Conference proceedings
    DOI 10.3205/21ebm084
    Database German Medical Science

    More links

    Kategorien

  4. Article: Aromatherapy in Palliative Care: A Single-Institute Retrospective Analysis Evaluating the Effect of Lemon Oil Pads against Nausea and Vomiting in Advanced Cancer Patients.

    Kreye, Gudrun / Wasl, Manuela / Dietz, Andrea / Klaffel, Daniela / Groselji-Strele, Andrea / Eberhard, Katharina / Glechner, Anna

    Cancers

    2022  Volume 14, Issue 9

    Abstract: Aromatherapy is regularly used in the University Hospital Krems's palliative care unit. In a retrospective analysis, we investigated whether there were improvements in nausea and vomiting in patients with advanced cancers over a time span of 24 months. ... ...

    Abstract Aromatherapy is regularly used in the University Hospital Krems's palliative care unit. In a retrospective analysis, we investigated whether there were improvements in nausea and vomiting in patients with advanced cancers over a time span of 24 months. Data collection used the medical records of patients who were institutionally approved to receive routine aroma applications for alleviating nausea and vomiting. The efficacy of using lemon oil pads was tested with one-dimensional chi-squared tests. Sixty-six patients received 222 applications of lemon oil on cotton pads; no data were available for 17 applications. The adequate relief of nausea and vomiting was reported for 149 (73%) applications, whereas no symptom control was seen for 56 (27%) applications. For the 56 applications without symptom control, first- and second-line rescue medications were successful in 53 and 3 cases, respectively. The use of aromatherapy with lemon oil pads against nausea and vomiting was feasible for 73% of all applications. All patients who did not benefit from aromatherapy had effective symptom control with a rescue medication. Large randomized prospective trials are necessary to evaluate the benefit of the use of lemon oil pads against nausea and vomiting in patients with advanced cancer.
    Language English
    Publishing date 2022-04-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14092131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.

    Van den Nest, Miriam / Glechner, Anna / Gold, Maria / Gartlehner, Gerald

    Systematic reviews

    2019  Volume 8, Issue 1, Page(s) 321

    Abstract: Background: Trastuzumab is a monoclonal antibody for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer, which is added to regular treatment and reduces mortality. Originally, trastuzumab had to be administered ... ...

    Abstract Background: Trastuzumab is a monoclonal antibody for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer, which is added to regular treatment and reduces mortality. Originally, trastuzumab had to be administered intravenously (IV) over 30 min every 3 weeks for 1 year. Since 2012, a formulation for the subcutaneous (SC) administration of trastuzumab has been available, which has not yet been approved in the USA. Advocates claim that the SC formulation saves time and money, despite higher costs. The purpose of this study is to review existing literature concerning the comparative efficacy and risk of harms of trastuzumab IV and SC concerning patient-relevant health outcomes.
    Methods: We conducted searches in the Cochrane Library and MEDLINE for articles published through May 2018 in English or German. In addition, we searched ClinicalTrials.gov to identify unpublished studies. We dually reviewed the abstracts and full-text articles based on a priori defined inclusion criteria, rated the risk of bias of included studies, and assessed the strength of the evidence for each outcome of interest. Because data was insufficient for quantitative synthesis, we summarized results narratively.
    Results: We identified three RCTs (randomized controlled trials) meeting our eligibility criteria, which included data on 1003 patients. We found moderate evidence for similar event rates (20.05% vs. 18%, HR (hazard ratio) 0.88, CI 95% = 0.62-1.27), and mortality rates (10% vs. 8%, HR 0.76, CI 95% = 0.44-1.32) after 1.7 years for patients receiving trastuzumab IV and for patients receiving SC. Results remained similar after 3.3 years, though evidence lacked strength due to a high dropout rate. All trials reported more adverse events among the SC group than in the IV group. Evidence for these findings was of moderate strength. Nevertheless, more than 85% of the patients preferred trastuzumab SC over IV. Results concerning serious adverse events appeared to be heterogeneous.
    Conclusion: Results of studies indicate similar efficacy between the two routes of administration. The higher rates of adverse events for SC administration were mainly attributable to injection site-related events. The clinical decision of whether to administer trastuzumab SC or IV requires the consideration of several factors and should be determined individually.
    MeSH term(s) Administration, Intravenous ; Antibodies, Monoclonal, Humanized/therapeutic use ; Breast Neoplasms/drug therapy ; Europe ; Female ; Humans ; Injections, Subcutaneous ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/drug effects ; Trastuzumab/therapeutic use ; Treatment Outcome ; United States
    Chemical Substances Antibodies, Monoclonal, Humanized ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
    Keywords covid19
    Language English
    Publishing date 2019-12-11
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2662257-9
    ISSN 2046-4053 ; 2046-4053
    ISSN (online) 2046-4053
    ISSN 2046-4053
    DOI 10.1186/s13643-019-1235-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: The importance of additional intracranial injuries in epidural hematomas: detailed clinical analysis, long-term outcome, and literature review in surgically managed epidural hematomas.

    Marhold, Franz / Prihoda, Romana / Pruckner, Philip / Eder, Vanessa / Glechner, Anna / Klerings, Irma / Gombos, Jozsef / Popadic, Branko / Antoni, Anna / Sherif, Camillo / Scheichel, Florian

    Frontiers in surgery

    2023  Volume 10, Page(s) 1188861

    Abstract: Objective: Epidural hematomas (EDH) occur in up to 8.2% of all traumatic brain injury patients, with more than half needing surgical treatment. In most patients suffering from this perilous disease, good recovery with an excellent clinical course is ... ...

    Abstract Objective: Epidural hematomas (EDH) occur in up to 8.2% of all traumatic brain injury patients, with more than half needing surgical treatment. In most patients suffering from this perilous disease, good recovery with an excellent clinical course is possible. However, the clinical course is mainly dependent on the presence of additional intracerebral injuries. Few studies comparing isolated and combined EDH in detail exist.
    Methods: We performed a retrospective single-center study from April 2002 to December 2014. The mean follow-up time was more than 6 years. In addition to analyzing diverse clinicoradiological data, we performed a systematic literature review dealing with a detailed comparison of patients with (combined) and without (isolated) additional intracerebral injuries.
    Results: We included 72 patients in the study. With increasing age, combined EDH had a higher incidence than isolated EDH. The mortality rate of the patients in the cohort was 10%, of which 0% had isolated EDH and 10% had combined EDH. Good recovery was achieved in 69% of patients, of which 91% had isolated EDH and 50% had combined EDH. A subgroup analysis of the different additional intracerebral injuries in combined EDH demonstrated no significant difference in outcome. A systematic literature review only identified six studies. Patients with isolated EDH had a statistically significantly lower mortality risk [relative risk (RR): 0.22; 95% CI: 0.12-0.39] and a statistically significantly lower risk of unfavorable Glasgow outcome scale score (RR: 0.21; 95% CI: 0.14-0.31) than patients with combined EDH.
    Conclusions: An excellent outcome in patients with surgically treated isolated EDH is possible. Furthermore, patients with combined EDH or isolated EDH with a low Glasgow coma scale (GCS) score may have favorable outcomes in 50% of the cases. Therefore, every possible effort for treatment should be made for this potentially lethal injury.
    Language English
    Publishing date 2023-08-01
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2773823-1
    ISSN 2296-875X
    ISSN 2296-875X
    DOI 10.3389/fsurg.2023.1188861
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk.

    Glechner, Anna / Wagner, Gernot / Mitus, Jerzy W / Teufer, Birgit / Klerings, Irma / Böck, Nina / Grillich, Ludwig / Berzaczy, Dominik / Helbich, Thomas H / Gartlehner, Gerald

    The Cochrane database of systematic reviews

    2023  Volume 3, Page(s) CD009632

    Abstract: Background: Screening mammography can detect breast cancer at an early stage. Supporters of adding ultrasonography to the screening regimen consider it a safe and inexpensive approach to reduce false-negative rates during screening. However, those ... ...

    Abstract Background: Screening mammography can detect breast cancer at an early stage. Supporters of adding ultrasonography to the screening regimen consider it a safe and inexpensive approach to reduce false-negative rates during screening. However, those opposed to it argue that performing supplemental ultrasonography will also increase the rate of false-positive findings and can lead to unnecessary biopsies and treatments.
    Objectives: To assess the comparative effectiveness and safety of mammography in combination with breast ultrasonography versus mammography alone for breast cancer screening for women at average risk of breast cancer.
    Search methods: We searched the Cochrane Breast Cancer Group's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), and ClinicalTrials.gov up until 3 May 2021.
    Selection criteria: For efficacy and harms, we considered randomised controlled trials (RCTs) and controlled non-randomised studies enrolling at least 500 women at average risk for breast cancer between the ages of 40 and 75. We also included studies where 80% of the population met our age and breast cancer risk inclusion criteria.
    Data collection and analysis: Two review authors screened abstracts and full texts, assessed risk of bias, and applied the GRADE approach. We calculated the risk ratio (RR) with 95% confidence intervals (CI) based on available event rates. We conducted a random-effects meta-analysis.
    Main results: We included eight studies: one RCT, two prospective cohort studies, and five retrospective cohort studies, enrolling 209,207 women with a follow-up duration from one to three years. The proportion of women with dense breasts ranged from 48% to 100%. Five studies used digital mammography; one study used breast tomosynthesis; and two studies used automated breast ultrasonography (ABUS) in addition to mammography screening. One study used digital mammography alone or in combination with breast tomosynthesis and ABUS or handheld ultrasonography. Six of the eight studies evaluated the rate of cancer cases detected after one screening round, whilst two studies screened women once, twice, or more. None of the studies assessed whether mammography screening in combination with ultrasonography led to lower mortality from breast cancer or all-cause mortality. High certainty evidence from one trial showed that screening with a combination of mammography and ultrasonography detects more breast cancer than mammography alone. The J-START (Japan Strategic Anti-cancer Randomised Trial), enrolling 72,717 asymptomatic women, had a low risk of bias and found that two additional breast cancers per 1000 women were detected over two years with one additional ultrasonography than with mammography alone (5 versus 3 per 1000; RR 1.54, 95% CI 1.22 to 1.94). Low certainty evidence showed that the percentage of invasive tumours was similar, with no statistically significant difference between the two groups (69.6% (128 of 184) versus 73.5% (86 of 117); RR 0.95, 95% CI 0.82 to 1.09). However, positive lymph node status was detected less frequently in women with invasive cancer who underwent mammography screening in combination with ultrasonography than in women who underwent mammography alone (18% (23 of 128) versus 34% (29 of 86); RR 0.53, 95% CI 0.33 to 0.86; moderate certainty evidence). Further, interval carcinomas occurred less frequently in the group screened by mammography and ultrasonography compared with mammography alone (5 versus 10 in 10,000 women; RR 0.50, 95% CI 0.29 to 0.89; 72,717 participants; high certainty evidence). False-negative results were less common when ultrasonography was used in addition to mammography than with mammography alone: 9% (18 of 202) versus 23% (35 of 152; RR 0.39, 95% CI 0.23 to 0.66; moderate certainty evidence). However, the number of false-positive results and necessary biopsies were higher in the group with additional ultrasonography screening. Amongst 1000 women who do not have cancer, 37 more received a false-positive result when they participated in screening with a combination of mammography and ultrasonography than with mammography alone (RR 1.43, 95% CI 1.37 to 1.50; high certainty evidence). Compared to mammography alone, for every 1000 women participating in screening with a combination of mammography and ultrasonography, 27 more women will have a biopsy (RR 2.49, 95% CI 2.28 to 2.72; high certainty evidence). Results from cohort studies with methodological limitations confirmed these findings. A secondary analysis of the J-START provided results from 19,213 women with dense and non-dense breasts. In women with dense breasts, the combination of mammography and ultrasonography detected three more cancer cases (0 fewer to 7 more) per 1000 women screened than mammography alone (RR 1.65, 95% CI 1.0 to 2.72; 11,390 participants; high certainty evidence). A meta-analysis of three cohort studies with data from 50,327 women with dense breasts supported this finding, showing that mammography and ultrasonography combined led to statistically significantly more diagnosed cancer cases compared to mammography alone (RR 1.78, 95% CI 1.23 to 2.56; 50,327 participants; moderate certainty evidence). For women with non-dense breasts, the secondary analysis of the J-START study demonstrated that more cancer cases were detected when adding ultrasound to mammography screening compared to mammography alone (RR 1.93, 95% CI 1.01 to 3.68; 7823 participants; moderate certainty evidence), whilst two cohort studies with data from 40,636 women found no statistically significant difference between the two screening methods (RR 1.13, 95% CI 0.85 to 1.49; low certainty evidence).
    Authors' conclusions: Based on one study in women at average risk of breast cancer, ultrasonography in addition to mammography leads to more screening-detected breast cancer cases. For women with dense breasts, cohort studies more in line with real-life clinical practice confirmed this finding, whilst cohort studies for women with non-dense breasts showed no statistically significant difference between the two screening interventions. However, the number of false-positive results and biopsy rates were higher in women receiving additional ultrasonography for breast cancer screening. None of the included studies analysed whether the higher number of screen-detected cancers in the intervention group resulted in a lower mortality rate compared to mammography alone. Randomised controlled trials or prospective cohort studies with a longer observation period are needed to assess the effects of the two screening interventions on morbidity and mortality.
    MeSH term(s) Female ; Humans ; Adult ; Middle Aged ; Aged ; Ultrasonography, Mammary ; Early Detection of Cancer ; Breast Neoplasms/diagnostic imaging ; Mammography ; Randomized Controlled Trials as Topic
    Language English
    Publishing date 2023-03-31
    Publishing country England
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ISSN 1469-493X
    ISSN (online) 1469-493X
    DOI 10.1002/14651858.CD009632.pub3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Conference proceedings: Retrieving clinically relevant information regarding the evidence-base from a guideline: an example using the 2017 DVO S3 Guideline on osteoporosis

    Thaler, Kylie / Biber, Nicole / Wagner, Gernot / Glechner, Anna

    2019  , Page(s) 19ebmP–OG09–09

    Event/congress 20. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin; EbM und Digitale Transformation in der Medizin; Berlin; Deutsches Netzwerk Evidenzbasierte Medizin e.V.; 2019
    Keywords Medizin, Gesundheit
    Publishing date 2019-03-20
    Publisher German Medical Science GMS Publishing House; Düsseldorf
    Document type Conference proceedings
    DOI 10.3205/19ebm123
    Database German Medical Science

    More links

    Kategorien

  9. Article: Die DVO Osteoporose Leitlinie: eine Analyse der Evidenzlage zu Bisphosphonaten. The DVO Osteoporosis Guideline: an analysis of the evidence on bisphosphonates

    Thaler, Kylie / Biber, Nicole / Glechner, Anna

    Osteologie

    2019  Volume 28, Issue 1, Page(s) 7

    Language German
    Document type Article
    ZDB-ID 1116704-x
    ISSN 1019-1291
    Database Current Contents Medicine

    More links

    Kategorien

  10. Article: [No title information]

    Thaler, Kylie / Biber, Nicole / Glechner, Anna

    Osteologie

    2019  Volume 28, Issue 01, Page(s) 7–13

    Abstract: Im Jahr 2017 veröffentlichte der Dachverband Osteologie (DVO) eine S3-Leitlinie zur Prophylaxe, Diagnose und Therapie der Osteoporose. Die Leitlinie war eine Aktualisierung der Version 2014 und basierte auf der ... ...

    Abstract Im Jahr 2017 veröffentlichte der Dachverband Osteologie (DVO) eine S3-Leitlinie zur Prophylaxe, Diagnose und Therapie der Osteoporose. Die Leitlinie war eine Aktualisierung der Version 2014 und basierte auf der Leitlinie der Scottish Intercollegiate Guidelines Network (SIGN) aus dem Jahr 2015. Die Update-Suche für 2014 bis 2016 wurde anhand der Methoden des AMWF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften) durchgeführt. Wir haben die Evidenz der DVO-Leitlinie 2017 hinsichtlich der Empfehlungen für Bisphosphonat-Therapie überprüft. Insbesondere ging es uns darum, die Anzahl der Studien, ihre Größe und die Studiendauer zu ermitteln, weiters die definierten Endpunkte, um die Evidenzgrundlage der Empfehlungen für die klinische Praxis zu beurteilen. Wir untersuchten dies mit Hilfe des Leitfadens und des zugehörigen Methodenberichts sowie der Web-Appendices. Wir extrahierten die zitierten Studien der DVO-Leitlinie 2017 für Bisphosphonat-Therapie in eine MS Excel-Tabelle. Zusätzlich wurden Referenzen ergänzt, die in der SIGN-Leitlinie 2015 und im Rahmen der Update-Suche für die DVO-Leitlinie 2017 zitiert wurden. Neben den beiden Leitlinienberichten identifizierten wir im Web-Appendix „Anhang A“ Evidenztabellen für einige der zitierten Studien. Wir haben dann eine Studienart (randomisierte kontrollierte Studie oder systematische Übersichtsarbeit) zugeordnet und die Evidenzstufe für jedes Zitat notiert. Wir fanden insgesamt 72 Zitate bezüglich der Wirksamkeit der Biphosphonat-Therapie. Davon waren in der DVO-Leitlinie 49 Zitate enthalten, in der SIGN-Leitlinie 21 (davon 9 Duplikate) sowie 11 Zitate, die im Rahmen der Update-Suche zitiert wurden, jedoch in der Leitlinie 2017 selbst nicht enthalten waren. Weiters identifizierten wir 62 Artikel, die unerwünschte Ereignisse untersuchten. 56 wurden in der DVO-Leitlinie genannt, sieben in der SIGN-Leitlinie (davon zwei Duplikate) und ein Artikel in der Updatesuche. Da die ursprüngliche DVO-Richtlinie keine Evidenztabellen verwendet hat, standen lediglich Informationen über die Anzahl und Art der TeilnehmerInnen, die Art der Interventionen (einschließlich Dosis) und die Ergebnisse der Artikel der Update-Suche zur Verfügung. Es lagen keine Zusammenfassungen von Ergebnistabellen- oder GRADE-Evidenzprofile vor. Wir verwendeten den Ansatz der besten Evidenz und beschrieben die vorliegende Evidenz der Bisphosphonat-Therapie anhand der berichteten Evidenzgrade (SIGN oder Oxford-System) und der Evidenzhierarchie.
    Keywords Leitlinie ; Osteoporose ; Bisphosphonate ; guideline ; osteoporosis ; bisphosphonate
    Language German
    Publishing date 2019-02-01
    Publisher © Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2113634-8
    ISSN 2567-5818 ; 1019-1291
    ISSN (online) 2567-5818
    ISSN 1019-1291
    DOI 10.1055/a-0800-0882
    Database Thieme publisher's database

    More links

    Kategorien

To top